Healthcare Industry News: blood glucose
News Release - June 19, 2006
OrSense's Non-Invasive Hemoglobin/Hematocrit Sensor Achieves Accurate PerformanceResults Presented by Professor Alain Berrebi at the 11th Congress of the European Hematology Association
NES ZIONA, Israel--(HSMN NewsFeed)--June 19, 2006--Results of a study presented by Prof. Alain Berrebi at the 11th Congress of the European Hematology Association (EHA), June 15-18, 2006 in Amsterdam, indicate that NBM-100, a non-invasive hemoglobin/hematocrit monitoring system developed by OrSense Ltd., accurately measures levels of hemoglobin/hematocrit in both hospital and ambulatory settings.
In order to investigate the use of the NBM-100 in hospitals and secondary medical environments, clinical trials were conducted in a blood donation center, an oncology clinic and a hematology clinic. The studies were carried out on a group of 304 adult subjects, 155 females and 149 males. The results provided by the NBM-100 were compared to measurements obtained by conventional invasive methods.
The mean hemoglobin/hematocrit level measured was the same for the invasive, venous measurements and the non-invasive NBM-100 measurements. The mean relative absolute error was 7.9% and the correlation between the two devices was r=0.9. The bias between the two methods was a negligible 0.4%.
"Non-invasive hemoglobin/hematocrit measurements have many potential advantages including the prevention of pain and potential transmission of infectious diseases and the reduced need for trained technicians," said Prof. Berrebi from the Institute of Hematology, Kaplan Medical Center, Rehovot, Israel and the principal investigator of the study. "Based on the study's conclusions, we believe that OrSense's non-invasive hemoglobin/hematocrit monitoring system could be used for accurate, safe and easy to operate anemia monitoring and early hemorrhage identification in hospitals, physicians' offices and blood donation centers," Prof. Berrebi concluded.
Lior D. Ma'ayan, Chief Executive Office, OrSense said, "Non-invasive measurements are key for early detection and monitoring of life threatening diseases. We believe that monitoring of patients in hospitals and at home will be transformed by the ability to deliver accurate and continuous non-invasive monitoring of critical blood parameters. OrSense is committed to answering the need for non-invasive monitoring of hemoglobin as well as glucose."
The NBM-100 uses a ring-shaped cuff applied to the patient's finger. The device is based on "Occlusion Spectroscopy", OrSense's proprietary measurement technology. This breakthrough technology enables, for the first time, the generation of optical signals across the finger which overcomes the key technological barrier related to the very low signal to noise ratio and non-specificity, inherent in competing approaches. Analysis of the signal provides the sensitivity necessary to measure hemoglobin/hematocrit concentrations, blood glucose levels and SpO2 levels.
OrSense is a medical device company developing non-invasive glucose monitoring systems for people with diabetes. The Company's products are based on its proprietary Occlusion Spectroscopy technology. OrSense also develops and markets non-invasive monitoring products for other critical blood parameters, such as hemoglobin. The Company's first commercial product is CE approved for monitoring hemoglobin and hematocrit. OrSense's intellectual property portfolio consists of 20 granted patents, with over 25 additional applications in process. Investors include Israel Health Care Ventures and STAR Ventures. For additional information, please visit OrSense's corporate Website at www.orsense.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.